|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diagnostic Ultrasound Urologix Medtronic Merck Sanofi-Synthelabo |
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00064649 |
The primary objective of this randomized clinical trial is to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride.
Condition | Intervention | Phase |
Benign Prostatic Hyperplasia |
Device: Transurethral Microwave Thermotherapy (TUMT) Device: Transurethral Needle Ablation (TUNA) Therapy Drug: Finasteride and Alfuzosin |
Phase III |
ChemIDplus related topics: | Finasteride Alfuzosin Alfuzosin hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia |
Enrollment: | 49 |
Study Start Date: | April 2004 |
Study Completion Date: | June 2006 |
Arms | Assigned Interventions |
2: Active Comparator
Transurethral Needle Ablation (TUNA)
|
Device: Transurethral Needle Ablation (TUNA) Therapy
type of minimally invasive surgical therapy for BPH
|
3: Active Comparator
finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
|
Drug: Finasteride and Alfuzosin
finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
|
1: Active Comparator
Transurethral Microwave Thermotherapy (TUMT)
|
Device: Transurethral Microwave Thermotherapy (TUMT)
type of minimally invasive surgical therapy for BPH
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion
Exclusion
United States, Colorado | |||||
University of Colorado Health Sciences Center | |||||
Denver, Colorado, United States, 80010 | |||||
United States, Illinois | |||||
Northwestern University | |||||
Chicago, Illinois, United States, 60611 | |||||
United States, Minnesota | |||||
Mayo Clinic | |||||
Rochester, Minnesota, United States, 55905 | |||||
United States, New York | |||||
Columbia University | |||||
New York, New York, United States, 10032 | |||||
United States, Texas | |||||
Baylor College of Medicine | |||||
Houston, Texas, United States, 77030 | |||||
University of Texas Southwestern Medical Center | |||||
Dallas, Texas, United States, 75390 | |||||
United States, Wisconsin | |||||
Medical College of Wisconsin | |||||
Milwaukee, Wisconsin, United States, 53226 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Diagnostic Ultrasound |
Urologix |
Medtronic |
Merck |
Sanofi-Synthelabo |
Study Chair: | Reginald Bruskewitz, M.D. | University of Wisconsin, Madison, WI |
Responsible Party: | George Washington University Biostatistics Center ( Kathryn Hirst/Coordinating Center Principal Investigator ) |
Study ID Numbers: | MIST, 5 U01 DK060817 |
First Received: | July 10, 2003 |
Last Updated: | December 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00064649 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|